Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 858-870

  Castro Gamero, Angel Mauricio ^a   Borges, Kleiton Silva ^a   Moreno, Daniel Antunes ^a   Suazo, Veridiana Kill ^a   Fujinami, Mayara Missono ^a   De Paula Gomes Queiroz, Rosane ^a   De Oliveira, Harley Francisco ^a   Carlotti Jr , Carlos Gilberto ^a   Scrideli, Carlos Alberto ^a   Tone, Luiz Gonzaga ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cdk1 gene; Drug combination; Glioblastoma; M4N; Survivin gene; Temozolomide

Indexed keywords

CYCLIN DEPENDENT KINASE 1; SURVIVIN; TEMOZOLOMIDE; TERAMEPROCOL; TRANSCRIPTION FACTOR SP1;

ADULT; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CHEMORADIOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE 1 GENE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GAMMA RADIATION; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; MALE; MITOSIS INDEX; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVIN 2B GENE; SURVIVIN GENE; UPREGULATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INHIBITORY CONCENTRATION 50; MALE; MASOPROCOL; MITOTIC INDEX; RADIATION-SENSITIZING AGENTS; RNA SPLICING; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 84880919391     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9917-4     Document Type: Article

References (67)

1. Khasraw M, Lassman AB (2010) Advances in the treatment of malignant gliomas. Curr Oncol Rep 12:26-33. doi: 10.1007/s11912-009-0077-4
2. Benítez JA, Domínguez-Monzón G, Segovia J (2008) Conventional and gene therapy strategies for the treatment of brain tumors. Curr Med Chem 15:729-742
3. Henson JW (2006) Treatment of glioblastoma multiforme: a new standard. Arch Neurol 63:337-341
4. Verheij M, Bartelink H (2000) Radiation-induced apoptosis. Cell Tissue Res 301:133-142. doi: 10.1007/s004410000188
5. Shah MA, Schwartz GK (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7(8):2168-2181
6. Sah NK, Khan Z, Khan GJ, Bisen PS (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244:164-171. doi: 10.1016/j.canlet.2006.03.007
7. Ambrosini G, Adida C, Sirugo G, Altieri DC (1998) Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273:11177-11182. doi: 10.1074/jbc.273.18.11177
8. Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22:8581-8589. doi: 10.1038/sj.onc.1207113
9. Ryan BM, O'Donovan N, Duffy MJ (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35:553-562. doi: 10.1016/j.ctrv.2009.05. 003
10. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC (2003) Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9:2683-2692
11. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20(4):1063-1068
12. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J (2004) Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23:7494-7506. doi: 10.1038/sj.onc.1208049
13. Reichert S, Rödel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M, Kaina B, Rödel F (2011) Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 101(1):51-58. doi: 10.1016/j.radonc.2011.06.037
14. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97(24):13103-13107. doi: 10.1073ypnas.240390697
15. Wang Q, Su L, Liu N, Zhang L, Xu W, Fang H (2011) Cyclin dependent kinase 1 inhibitors: a review of recent progress. Curr Med Chem 18(13):2025-2043
16. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222-231
17. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3):153-166. doi: 10.1038/nrc2602
18. Bodey B, Siegel SE, Kaiser HE (2002) Expression of proline-directed protein kinase, (p34cdc2/p58cyclin A), a novel cell proliferation marker in childhood brain tumors. In Vivo 16:589-594
19. Chen H, Huang Q, Dong J, Zhai DZ, Wang AD, Lan Q (2008) Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo. BMC Cancer 8:29. doi: 10.1186/1471-2407-8-29
20. Heller JD, Kuo J, Wu TC, Kast WM, Huang RC (2001) Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo. Cancer Res 61:5499-5504
21. Chang CC, Heller JD, Kuo J, Huang RC (2004) Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A 101(36):13239-13244. doi: 10.1073/pnas.0405407101
22. Grossman SA, Ye X, Peereboom D, Rosenfeld MR, Mikkelsen T, Supko JG, Desideri S, Adult Brain Tumor Consortium (2012) Phase I study of terameprocol in patients with recurrent high-grade gliomas. Neuro-Oncology 14(4):511-517. doi: 10.1093/neuonc/nor230
23. Louis DN, Ohgaki H, Wiestler OD (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109. doi: 10.1007/s00401-007-0243-4
24. Borges KS, Castro-Gamero AM, Moreno DA, da Silva Silveira V, Brassesco MS, de Paula Queiroz RG, de Oliveira HF, Carlotti CG Jr, Scrideli CA, Tone LG (2012) Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. J Cancer Res Clin Oncol 138(3):405-414. doi: 10.1007/s00432-011-1111-0
25. Brassesco MS, Valera ET, Neder L, Castro-Gamero AM, Arruda D, Machado HR, Sakamoto-Hojo ET, Tone LG (2009) Polyploidy in atypical choroid plexus papilloma of the posterior fossa. Neuropathology 29:293-298. doi: 10.1111/j.1440-1789.2008.00949.x
26. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25(4):402-408. doi: 10.1006/meth.2001.1262
27. Valente V, Teixeira SA, Neder L, Okamoto OK, Oba-Shinjo SM, Marie SK, Scrideli CA, Paçó-Larson ML, Carlotti CG Jr (2009) Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol Biol 10:17. doi: 10.1186/1471-2199-10-17
28. Castro-Gamero AM, Borges KS, da Silva Silveira V, Lira RC, de Paula Gomes Queiroz R, Valera FC, Scrideli CA, Umezawa K, Tone LG (2012) Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. Anticancer Drugs 23(6):638-650. doi: 10.1097/CAD.0b013e328350e835
29. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27-55
30. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315-2319. doi: 10.1038/nprot.2006.339
31. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453. doi: 10.2353/ajpath.2007.070011
32. Shirahata M, Oba S, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Ishii S, Takahashi JA, Kato K (2009) Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. Cancer Sci 100:165-172. doi: 10.1111/j.1349-7006.2008.01002.x
33. Perry J, Okamoto M, Guiou M, Shirai K, Errett A, Chakravarti A (2012) Novel therapies in glioblastoma. Neurol Res Int 2012:428-565. doi: 10.1155/2012/428565
34. Lackner MR, Wilson TR, Settleman J (2012) Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol 8(8):999-1014. doi: 10.2217/fon.12.86
35. Altieri DC (2008) New wirings in the survivin networks. Oncogene 27:6276-6284. doi: 10.1038/onc.2008.303
36. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24(11):1770-1783. doi: 10.1200/JCO.2005.03.7689
37. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, Tsuji M, Kami K, Miyatake S (2003) Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 99(4):738-745
38. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5:2086-2095
39. Lambert JD, Meyers RO, Timmermann BN, Dorr RT (2001) Tetra-O- methylnordihydroguaiaretic acid inhibits melanoma in vivo. Cancer Lett 171:47-56. doi: 10.1016/S0304-3835(01)00560-2
40. Meyers RO, Lambert JD, Hajicek N, Pourpak A, Kalaitzis JA, Dorr RT (2009) Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid. Bioorg Med Chem Lett 19:4752-4755. doi: 10.1016/j.bmcl.2009.06.063
41. Park R, Chang CC, Liang YC, Chung Y, Henry RA, Lin E, Mold DE, Huang RC (2005) Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. Clin Cancer Res 11:4601-4609. doi: 10.1158/1078-0432.CCR-04-2188
42. Mak DH, Schober WD, Chen W, Heller J, Andreeff M, Carter BZ (2007) Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma 48:774-785. doi: 10.1080/10428190601186143
43. Zhu X, Ma Y, Liu D (2010) Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol 3:17. doi: 10.1186/1756-8722-3-17
44. Hansel DE, Dhara S, Huang RC et al (2005) CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol 29:390-399
45. Lopez RA, Goodman AB, Rhodes M, Blomberg JA, Heller J (2007) The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration. Anticancer Drugs 18:933-939. doi: 10.1097/CAD.0b013e32813148e0
46. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67. doi: 10.1186/1476-4598-5-67
47. Shah MA, Schwartz GK (2000) The relevance of drug sequence in combination chemotherapy. Drug Resist Updat 3(6):335-356. doi: 10.1054/drup.2000.0165
48. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M (2002) Transcriptional repression of the antiapoptotic survivin gene by wild type p53. J Biol Chem 277(5):3247-3257. doi: 10.1074/jbc.M106643200
49. Yamamoto H, Ngan CY, Monden M (2008) Cancer cells survive with survivin. Cancer Sci 99(9):1709-1714. doi: 10.1111/j.1349-7006.2008.00870.x
50. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9(3):469-479
51. Sun Y, Giacalone NJ, Lu B (2011) Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma. J Thorac Oncol 6(1):8-14. doi: 10.1097/JTO.0b013e3181fa646a
52. Iwasa T, Okamoto I, Suzuki M et al (2008) Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 14:6496-6504. doi: 10.1158/1078-0432.CCR-08- 0468
53. Cao C, Mu Y, Hallahan DE, Lu B (2004) XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23:7047-7052. doi: 10.1038/sj.onc.1207929
54. Rödel F, Frey B, Leitmann W, Capalbo G, Weiss C, Rödel C (2008) Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 71:247-255. doi: 10.1016/j.ijrobp.2008.02.011
55. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Kawaguchi Y, Fujimoto K, Wada M, Miyatake S, Imamura M (2005) Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 138:299-305. doi: 10.1016/j.surg.2005.05.009
56. Eisele G, Weller M (2011) Targeting apoptosis pathways in glioblastoma. Cancer Lett. doi: 10.1016/j.canlet.2010.12.012 [Epub ahead of print]
57. Sgorbissa A, Tomasella A, Potu H, Manini I, Brancolini C (2011) Type I IFNs signaling and apoptosis resistance in glioblastoma cells. Apoptosis 16(12):1229-1244. doi: 10.1007/s10495-011-0639-4
58. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, Pearson A, Vassal G, Workman P (2010) Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 9(5):1219-1233. doi: 10.1158/1535-7163.MCT-09-0683
59. Valera ET, de Freitas Cortez MA, de Paula Queiroz RG, de Oliveira FM, Brassesco MS, Jabado N, Faury D, Bobola MS, Machado HR, Scrideli CA, Tone LG (2009) Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine. Childs Nerv Syst 25(1):39-45. doi: 10.1007/s00381-008-0740-3
60. Bax DA, Little SE, Gaspar N et al (2009) Molecular and phenotypic characterisation of paediatric gliomas cell lines as models for preclinical drug development. PLoS One 4(4):e5209. doi: 10.1371/journal.pone.0005209
61. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD (1999) Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59(24):6097-6102
62. Sampath J, Pelus LM (2007) Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol 43:174-191
63. Wang HW, Sharp TV, Koumi A, Koentges G, Boshoff C (2002) Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpes virus which resembles a spliced variant of human survivin. EMBO J 21(11):2602-2615. doi: 10.1093/emboj/21.11.2602
64. Zhu N, Gu L, Findley HW, Li F, Zhou M (2004) An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 2345:7545-7551. doi: 10.1038/sj.onc.1208038
65. Ling X, Cheng Q, Black JD, Li F (2007) Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem 282(37):27204-27214. doi: 10.1074/jbc.M705161200
66. Zheng WY, Kang YY, Li LF, Xu YX, Ma XY (2011) Levels of effectiveness of gene therapies targeting survivin and its splice variants in human breast cancer cells. Drug Discov Ther 5(6):293-298. doi: 10.5582/ddt.2011.v5.6.293
67. Jacob NK, Cooley JV, Shirai K, Chakravarti A (2012) Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation. Onco Targets Ther 5:7-20. doi: 10.2147/OTT.S28147